Our co-founders, Dave Llewellyn and Joe Illingworth, were recognized in Endpoints News’ “20 Under 40” list. This list honors biotech leaders under the age of 40 who’ve already made a mark and will likely make an even bigger impact in the years to come. Learn more about how Dave and Joe took DJS’ cutting-edge antibody discovery platform from concept to biotech, and now to AbbVie.
Learn more here: https://endpts.com/the-202-under-40-your-guide-to-the-next-generation-of-biotech-leaders/
